Kura Oncology, Inc. (KURA)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: chart score 2/5 — price 10.53 below SMA20 11.16, SMA50 11.19, EMA9 10.77 and EMA21 11.13 with MACD -0.31 < 0 and five straight red candles; no tradable bullish setup (score >= 3 required). Pullback limit toward the 10.29-10.36 shelf is countertrend (price < SMA50 with MACD < 0) → blocked by the trend-alignment gate. No breakout stop qualifies either: above the 10.89-10.97 highs the falling SMA20/SMA50 band (11.16/11.19) is immediate supply and momentum is negative — no qualifying breakout pattern.
Company overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its portfolio includes KOMZIFTI, a menin inhibitor, and Darlifarnib, which is in early-stage trials for solid tumors. The company also explores next-generation menin inhibitors for diabetes and cardiometabolic disorders.
Fundamental
fairKura Oncology's fundamentals are mixed, with a strong cash position and product launch offset by deep losses and single-product risk.
Mixed fundamentals. A strong balance sheet ($519M cash and short-term investments versus $24.5M debt; runway into Q4 2027; no going-concern, covenant or litigation red flags in SEC filings), a ramping first-product launch and the validating Kyowa Kirin partnership are offset by deep losses, accelerating cash burn, single-product concentration and an expected future funding need. The stock trades below both DCF model values and sell-side targets, but loss-based valuation multiples are non-meaningful. Overall: balanced-to-uncertain; best suited to risk-tolerant, catalyst-driven investors.
Sentiment
fairSentiment is mildly positive with recent catalysts but lacks forward-dated drivers.
Dominant recent catalysts are a JPMorgan Overweight initiation (announced 2026-10-01, $30 price target) and reception-positive KO-7246 diabetes data from EASD (2026-09-29) — both only partially absorbed — while the larger Caspian Therapeutics launch (9/9) and CFO appointment (9/8) sit outside the trailing actionability window. Sentiment delta is essentially flat (baseline ≈ +0.10 vs scoring ≈ +0.15; both windows mildly positive) and the Red-Flag Screen is clean — no severe or moderate flags fired — with the setup held back by the absence of a forward-dated driver and heavy routine insider-sale headline flow.
Technical
weakThe technical analysis indicates a weak-bearish trend with no tradable bullish pattern.
Trend frame: price 10.53 sits below SMA20 11.16, SMA50 11.19, EMA9 10.77, EMA21 11.13, WMA9 10.65, WMA21 10.96 and the 10.63 daily VWAP; only SMA200 9.81 remains below price. Momentum frame: RSI14 37.59 weak (not oversold), Williams %R -87.43 oversold but unconfirmed, MACD -0.31/-0.21/-0.10 (line below signal, both below zero), ADX14 17.58 — no directional strength; read against a below-MA price it is a weak-bearish drift, not a bull trend. Volatility: ATR14 0.52 (~4.9% of price), StdDev20 0.48, last-session range 0.55 ~ 1.1x ATR (no range-expansion day). Volume: avgDollarVolume20 ~ $20.8M; last-3-session regular dollar volume ~ $12.96M — liquid. The tape is a decelerating decline from the Aug 25 high 13.90 into a defended 10.29-10.36 shelf, with five straight red candles — bounce-only at best. No tradable bullish pattern: a pullback/oversold limit toward the shelf is countertrend (price 10.53 < SMA50 11.19 with MACD -0.31 < 0 → trend-alignment gate), and no breakout base exists above the 10.89-10.97 highs. Score 2/5; Do Nothing.
You’re looking at 2026-10-06 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

